Proteomics

Dataset Information

0

LC-MSMS of primary AML class I immunopeptidome (ERE-derived MAPs identification approach)


ABSTRACT: The development of therapeutic anticancer vaccines calls for the identification of tumor-specific antigens (TSAs). Though a combination of four cutting-edge proteogenomic approaches, we performed a deep exploration of the MHC-I presented peptides (MAPs) of 19 acute myeloid leukemia (AML) patients and identified various TSAs that could serve for the design of an anti-AML vaccine.

INSTRUMENT(S): Q Exactive HF

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Mononuclear Cell, Bone Marrow, Blood

DISEASE(S): Acute Myeloid Leukemia

SUBMITTER: Courcelles Mathieu  

LAB HEAD: Pierre Thibault

PROVIDER: PXD018542 | Pride | 2021-03-19

REPOSITORIES: pride

Dataset's files

Source:
Action DRS
05H143_131118_1.mgf Mgf
05H143_131118_1.pride.mgf.gz Mgf
05H143_131118_1.raw Raw
05H143_131118_2.mgf Mgf
05H143_131118_2.pride.mgf.gz Mgf
Items per page:
1 - 5 of 154
altmetric image

Publications


Acute myeloid leukemia (AML) has not benefited from innovative immunotherapies, mainly because of the lack of actionable immune targets. Using an original proteogenomic approach, we analyzed the major histocompatibility complex class I (MHC class I)-associated immunopeptidome of 19 primary AML samples and identified 58 tumor-specific antigens (TSAs). These TSAs bore no mutations and derived mainly (86%) from supposedly non-coding genomic regions. Two AML-specific aberrations were instrumental in  ...[more]

Similar Datasets

2021-03-19 | PXD018540 | Pride
2021-03-19 | PXD018543 | Pride
2021-03-19 | PXD018541 | Pride
2021-03-19 | PXD018539 | Pride
2019-01-31 | E-MTAB-7607 | biostudies-arrayexpress
2019-07-17 | PXD012083 | Pride
2018-10-18 | GSE113972 | GEO
2019-11-20 | GSE127825 | GEO
2018-10-18 | GSE111092 | GEO
2018-01-01 | GSE96540 | GEO